BackAltamira Therapeutics Overview

Altamira Therapeutics Total Liabilities

Track Altamira Therapeutics's total liabilities ($2.1M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$2.09M
68.92% YoYΔ $851488.00 vs prior year quarter

Peer average

Loading

Altamira Therapeutics Total Liabilities History

Loading

Altamira Therapeutics vs. peers: Total Liabilities Comparison

Loading

Altamira Therapeutics Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Altamira Therapeutics (CYTO) FAQ

As of the most recent data (December 2024), CYTO shows a total liabilities of $2.1M. That compares with $1.2M in the prior-year period — up 68.9% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CYTO's total liabilities is now $2.1M (was $1.2M) — a 68.9% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Altamira Therapeutics is outperforming or lagging.

Tracking CYTO's total liabilities over time shows whether Altamira Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $2.1M That compares with $1.2M in the prior-year period — up 68.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total liabilities page, Stockcircle has Altamira Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total liabilities (currently $2.1M) with ownership activity and broader fundamentals.

Altamira Therapeutics's total liabilities is $2.1M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.